Zúñiga-González S, Pérez-Rodríguez P

Language: Spanish
References: 0
Page: 171-174
PDF size: 82.21 Kb.

ABSTRACT

Objective: To observe metimazole influence when is administrated previously to radioiodine in Graves’ thyrotoxicosis treatment. Material and methods: We evaluated 75 patients 20-65 years, old, with Graves’ disease diagnosis. Patients were assigned in two groups. In Group “A 41 patients received Methimazole (MTZ) and propranolol by 6 months, receiving 1-3 weeks after 10 mCi I¹³¹, when hyperthyroidism return. Group B, with 34 patients, received initially 10 mCi I¹³¹ plus propranolol. The patients were observed 6 months after the radioactive iodine. Two factors ANOVA, Student t, and squared Chi were used for statistical analysis. Results: Were excluded 11 patients in A group, 4 in B group. In A group, 21 patients (70%) developed hypothyroidism 4-6 months after radioiodine, and 6 patients (20%) presented normal thyroid function. Three patients (10%) stay in hyperthyroidism after 6 months and received a radioactive iodine again. In group B, 24 patients (80%) presented hypothyroidism between 6 months after radioiodine, 6 patients (20%) received again I¹³¹ (X² = 0.52 p = 0.47). After the radioiodine (Firsth doses), development hypothyroidism in A group at 4.57 ± 0.3 months and 3.0 ± 0.9 in the B group with significant difference (p= 0.0001) Conclusion: Methimazole used previously to treatment with radioiodine therapy, not decreased the effectiveness of treatment although the group without methimazole show more easy hypothyroidism.